Bristol-Myers Beats On Plavix

4 The drugmaker climbed 4% to 23.13 after it said its Q4 EPS rose 39% to 46 cents ex items, beating views by 5 cents. Sales grew 4% to $5.25 bil. Bristol-Myers Squibb (BMY) credited strong sales of its blood thinner Plavix, which accounted for $1.5 bil in sales. It sees '09 EPS of $1.85-$2.00 vs. views of $1.95, but cautioned that the recession may curb patient and gov't spending.

is a subscriber feature. Take a free trial now to get instant access.

Try the Digital + Weekly Print Combo and enjoy the best of both worlds!eIBD is available after market close to give you a head start on the next day's market action. Plus, you get the Weekly Special print edition delivered right to your home or office!

Select market data is provided by Interactive Data Corp. Real Time Services. Price and Volume data is delayed 20 minutes unless otherwise noted, is believed accurate but is not warranted or guaranteed by Interactive Data Corp. Real Time Services and is subject to Interactive Data Corp. Real Time Services terms. All times are Eastern United States. *Reflects real-time index prices.